Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196)
China
· Delayed Price · Currency is CNY | Market Cap | 66.45B |
| Revenue (ttm) | 41.61B |
| Net Income (ttm) | 2.11B |
| Shares Out | 2.66B |
| EPS (ttm) | 0.78 |
| PE Ratio | 35.51 |
| Forward PE | 23.64 |
| Dividend | 0.27 (0.98%) |
| Ex-Dividend Date | Aug 6, 2024 |
| Volume | 38,300,601 |
| Open | 27.50 |
| Previous Close | 27.48 |
| Day's Range | 27.49 - 28.34 |
| 52-Week Range | 20.38 - 30.44 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2024 |
About Shanghai Fosun Pharmaceutical (Group)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the tr... [Read more]
Financial Performance
In 2023, Shanghai Fosun Pharmaceutical (Group)'s revenue was 41.40 billion, a decrease of -5.81% compared to the previous year's 43.95 billion. Earnings were 2.39 billion, a decrease of -36.04%.
Financial StatementsNews
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech
Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.
China's health-care sector may be next to face regulatory crackdown, says economist
Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...
Pandemic Accelerates China's Drive Into mRNA Treatments
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan...
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma...
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co...
Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations
Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.